Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CYTK
SELLCytokinetics, Incorporated · Healthcare · United States · $11.0B · Avg Vol: $182M/d
COMPANY DESCRIPTION
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors for the treatment of debilitating diseases. Its competitive moat lies in a proprietary drug discovery platform targeting muscle function, with a lead candidate currently in advanced clinical trials for heart failure. Cytokinetics is a clinical-stage biotech firm specializing in muscle biology, aiming to address significant unmet medical needs in cardiovascular and neuromuscular diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.6M | 7.5M | 18.5M | 88.0M | -2.4% | 105.8M | 112.9M | — | 28.2% |
| EPS | -4.33 | -5.45 | -5.26 | -6.54 | — | -6.76 | -6.32 | -4.68 | — |
| Shares | 94.8M | 101.6M | 118.2M | 122.9M | +29.6% | 135.8M | — | — | — |
| Debt | 750.3M | 755.8M | 788.7M | 1.3B | 19.6% | 1.4B | — | — | — |
| Equity | -107.9M | -386.3M | -135.4M | -659.6M | — | — | — | — | — |
| Op CF | -299.5M | -414.3M | -395.9M | -510.0M | — | -523.8M | — | — | — |
| Inv CF | -262.1M | 239.3M | -553.1M | 16.7M | — | — | — | — | — |
| Fin CF | 516.2M | 221.3M | 930.6M | 524.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CYTK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated(you) | $11.0B | 26 | SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 28 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 28 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| IBRX | ImmunityBio, Inc. | $7.4B | 28 | SELL |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| COGT | Cogent Biosciences, Inc. | $6.8B | 26 | SELL |
| CGON | CG Oncology, Inc. | $6.1B | 26 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%